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2013, accepted Fever the past decade, myocardial structure, cardiomyocyte function, and intramyocardial signaling were shown to be
speciﬁcally altered in heart failure with preserved ejection fraction (HFPEF). A new paradigm for HFPEF development
is therefore proposed, which identiﬁes a systemic proinﬂammatory state induced by comorbidities as the cause of
myocardial structural and functional alterations. The new paradigm presumes the following sequence of events in
HFPEF: 1) a high prevalence of comorbidities such as overweight/obesity, diabetes mellitus, chronic obstructive
pulmonary disease, and salt-sensitive hypertension induce a systemic proinﬂammatory state; 2) a systemic
proinﬂammatory state causes coronary microvascular endothelial inﬂammation; 3) coronary microvascular
endothelial inﬂammation reduces nitric oxide bioavailability, cyclic guanosine monophosphate content, and protein
kinase G (PKG) activity in adjacent cardiomyocytes; 4) low PKG activity favors hypertrophy development and
increases resting tension because of hypophosphorylation of titin; and 5) both stiff cardiomyocytes and interstitial
ﬁbrosis contribute to high diastolic left ventricular (LV) stiffness and heart failure development. The new HFPEF
paradigm shifts emphasis from LV afterload excess to coronary microvascular inﬂammation. This shift is supported
by a favorable Laplace relationship in concentric LV hypertrophy and by all cardiac chambers showing similar
remodeling and dysfunction. Myocardial remodeling in HFPEF differs from heart failure with reduced ejection
fraction, in which remodeling is driven by loss of cardiomyocytes. The new HFPEF paradigm proposes comorbidities,
plasma markers of inﬂammation, or vascular hyperemic responses to be included in diagnostic algorithms and
aims at restoring myocardial PKG activity. (J Am Coll Cardiol 2013;62:263–71) ª 2013 by the American College
of Cardiology FoundationSee page 272Insight into myocardial structure and function in heart failure
(HF) with preserved ejection fraction (HFPEF) has long been
missing because of a lack of myocardial tissue obtained from
HFPEF patients (1). Over the past decade, several groups of
investigators were able to obtain myocardial tissue from
patients with HFPEF (2–6) or left ventricular (LV) diastolic
dysfunction (7,8). These studies revealed speciﬁc alterations in
myocardial structure and function that were relevant to
concentric LV remodeling and diastolic LV dysfunction
characteristically observed in patients with HFPEF (9,10).
Structural alterations consisted of cardiomyocyte hypertrophy
(3) and interstitialﬁbrosis (2–4,6),whereas functional changes
included incomplete relaxation of myocardial strips (7) and
increased cardiomyocyte stiffness (2–4,8). The same stud-
ies also demonstrated abnormal intramyocardial signalingent of Physiology, Institute for Cardiovascular Research VU, VU
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bruary 5, 2013.evident from endothelial cells expressing adhesion molecules
(5), inﬂammatory cells secreting proﬁbrotic transforming
growth factor b (TGF-b) (5) and oxidative stress increasing
nitrotyrosine content (4,5). This abundance of new data on
myocardial structure, function, and signaling allows for a new
paradigm on myocardial remodeling and dysfunction in
HFPEF. This new paradigm reconciles the recently acquiredknowledge on myocardial structure, function, and signaling
with novel insights on the importance of comorbidities in
HFPEF (11).
A New Paradigm for HFPEF
As outlined in Figure 1, the new paradigm proposes that
myocardial remodeling and dysfunction in HFPEF results
from a sequence of events consisting of the following:
1) comorbidities and especially obesity induce a systemic
proinﬂammatory state; 2) because of this proinﬂammatory
state, coronary microvascular endothelial cells produce





ARB = angiotensin II
receptor blocker
BNP = B-type natriuretic
peptide
cGMP = cyclic guanosine
monophosphate
DM = diabetes mellitus
HF = heart failure
HFPEF = heart failure with
preserved ejection fraction
HFREF = heart failure with
reduced ejection fraction
IL = interleukin
LV = left ventricular
PDE5 = phosphodiesterase 5
PH-HFPEF = pulmonary
hypertension secondary to
heart failure with preserved
ejection fraction
PKG = protein kinase G
ROS = reactive oxygen
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TGF = transforming growth
factor
TNF = tumor necrosis factor
VCAM = vascular cell
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264(NO) bioavailability for adjacent
cardiomyocytes; 3) limited NO
bioavailability decreases protein
kinase G (PKG) activity in car-
diomyocytes; 4) low PKG activity
removes the brake on cardiomyo-
cyte hypertrophy, thereby induc-
ing concentric LV remodeling,
and stiffens the cardiomyocyte be-
cause of hypophosphorylation of
the giant cytoskeletal protein titin;
and 5) both stiff cardiomyocytes
and increased collagen deposition
by myoﬁbroblasts cause diastolic
LV dysfunction, the major cardiac
functional deﬁcit in HFPEF.
Comorbidities in HFPEF and a
systemic proinﬂammatory state.
Noncardiac comorbidities are
highly prevalent in HFPEF (11).
The most important are over-
weight/obesity, hypertension, di-
abetes mellitus (DM), chronic
obstructive pulmonary disease,
anemia, and chronic kidney dis-
ease. All these comorbidities have
the ability to induce a systemic
inﬂammatory state. Chronic in-
ﬂammation is obvious in chronic
obstructive pulmonary disease,
which is both a premorbid iden-
tiﬁer of HFPEF (12) and aFigure 1
Comorbidities Drive Myocardial Dysfunction and
Remodeling in HFPEF
Comorbidities induce a systemic proinﬂammatory state with elevated plasma
levels of interleukin (IL)-6, tumor necrosis factor (TNF)-a, soluble ST2 (sST2), and
pentraxin 3. Coronary microvascular endothelial cells reactively produce reactive
oxygen species (ROS), vascular cell adhesion molecule (VCAM), and E-selectin.
Production of ROS leads to formation of peroxynitrite (ONOO) and reduced nitric
oxide (NO) bioavailability, both of which lower soluble guanylate cyclase (sGC)
activity in adjacent cardiomyocytes. Lower sGC activity decreases cyclic guanosine
monophosphate concentration and protein kinase G (PKG) activity. Low PKG
activity increases resting tension (Fpassive) of cardiomyocytes because of hypo-
phosphorylation of titin and removes the brake on prohypertrophic stimuli inducing
cardiomyocyte hypertrophy. VCAM and E-selectin expression in endothelial cells
favors migration into the subendothelium of monocytes. These monocytes release
transforming growth factor b (TGF-b). The latter stimulates conversion of ﬁbro-
blasts to myoﬁbroblasts, which deposit collagen in the interstitial space. COPD ¼
chronic obstructive pulmonary disease; HFPEF ¼ heart failure with preserved
ejection fraction.contributor to HFPEF mortality (11). In visceral obesity,
adipose tissue is inﬁltrated by macrophages, which produce
a systemic inﬂammatory state because of secretion of pro-
inﬂammatory cytokines (13,14). Obesity also contributes
to mortality as evident from the U-shaped relationship in
HFPEF between body mass index and mortality (15). In salt-
sensitive hypertension, high salt intake leads to systemic
oxidative stress (16), possibly because of renal production of
proinﬂammatory cytokines (17), and in HF with or without
anemia, iron deﬁciency contributes to immune responses and
oxidative stress (18). Comorbidities were recently shown to be
accompanied by a greater deterioration of myocardial function
and structure in HFPEF than in arterial hypertension (19).
This ﬁnding supports additional deterioration in HFPEF by
HF-related mechanisms such as neuroendocrine activation
(20) and the lack of high-energy phosphates (21). Additional
involvement of HF-related mechanisms also explains the
poorer outcome of HFPEF than of comorbidities (22).
The systemic inﬂammatory state induced by these
comorbidities has recently been shown to be predictive of
incident HFPEF but not of incident HF with reduced
ejection fraction (HFREF) (23). In this study, the systemic
inﬂammatory state was evident from high circulating
levels of interleukin 6 (IL-6) and tumor necrosis factora (TNF-a). The same cytokines were also elevated in a
cross-sectional study of HFPEF patients (24). Furthermore,
similar cross-sectional studies revealed high plasma levels of
other inﬂammatory markers such as soluble ST2 (25), or
pentraxin 3 (26).
Coronary microvascular endothelial inﬂammation and
NO bioavailability. The systemic inﬂammatory state
induced by HFPEF comorbidities affects the coronary
microvascular endothelium as evident from the recently
established expression of endothelial adhesion molecules in
myocardial biopsy samples of HFPEF patients. Both
vascular cell adhesion molecule (VCAM) and E-selectin
were shown to be abundantly expressed (5,27). Their
expression leads to activation and subendothelial migration
of circulating leukocytes (5). Proinﬂammatory cytokines are
also known to elicit endothelial production of ROS through
activation of nicotinamide adenine dinucleotide phosphate
oxidases (28). This could explain the high nitrosative/
oxidative stress, which was recently visualized in HFPEF
myocardium using both nitrotyrosine and dihydroethidium
staining (4,5). High nitrotyrosine expression also suggests
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265low NO bioavailability in HFPEF myocardium because of
diversion of NO to peroxynitrite by superoxide anion.
Apart from inducing a systemic inﬂammatory state, cer-
tain comorbidities, such as DM, and physiological processes,
such as aging, can also directly enhance endothelial ROS
production. Exposure of endothelial cells to high glucose
induces mitochondrial fragmentation and dysfunction, ROS
production, and nitrotyrosine formation (29). Endothelial
mitochondrial dysfunction has also been shown to increase
with age (30).
As a result of coronary microvascular endothelial inﬂam-
mation, the vasodilator response of the coronary microvascular
bed to acetylcholine was reduced in HFPEF (31). The re-
duced vasodilator response correlated with LV diastolic
dysfunction (31). Similar paracrine endocardial-myocardial
interactions had previously already been reported (32). Sev-
eral recent studies emphasized the importance of a deﬁcient
systemic vasodilator response for the reduced exercise toler-
ance of HFPEF patients (33). Probably because of upre-
gulation of endothelial nitric oxide synthase, this response was
reversed after an exercise training program (34), which im-
proved both exercise capacity and diastolic LV dysfunction
(35). Peripheral endothelial dysfunction was recently also id-
entiﬁed as an independent predictor of outcome of HFPEF
patients (36). This prognostic implication suggests a causal
involvement of endothelial dysfunction in HFPEF (37).
Low NO bioavailability and PKG activity. In cardiomy-
ocytes adjacent to dysfunctional endothelium, low NO
bioavailability and high peroxynitrite level predispose to
reduced cyclic guanosine monophosphate (cGMP) produc-
tion by soluble guanylate cyclase (38). Both low cGMP
content and low PKG activity were recently demonstrated in
myocardial homogenates of HFPEF patients (4). Of interest
was the inability of B-type natriuretic peptide (BNP)–
particulate guanylate cyclase signaling to normalize cGMP
content in HFPEF myocardium (4). This failure relates to
the low diastolic wall stress prevailing in a concentrically
remodeled left ventricle (39), is consistent with the lower
BNP levels frequently observed in HFPEF patients (20,40),
and supports use in HFPEF of neprilysin inhibition to
reduce BNP breakdown (41).
Low PKG activity and cardiomyocyte hypertrophy, re-
laxation, and stiffness. PKG functioning as a brake on
myocardial hypertrophy has been observed in a wide variety of
experimental and clinical settings. In cardiomyocytes cultured
from neonatal rat hearts, NO or a cGMP analogue attenuated
the norepinephrine-induced hypertrophic response (42). In
mice subjected to transverse aortic constriction, sildenaﬁl,
which increases myocardial PKG activity through inhibited
breakdown of cGMP by phosphodiesterase 5 (PDE5), pre-
vented or reversed cardiomyocyte hypertrophy and interstitial
ﬁbrosis by deactivating multiple prohypertrophic pathways
(43). In patients with diabetic cardiomyopathy and concentric
LV remodeling, sildenaﬁl treatment reduced the LV mass/
volume ratio (44). In line with these experimental and clinical
ﬁndings, lower myocardial PKG activity in HFPEF thanin HFREF was recently shown to correlate with a larger
cardiomyocyte diameter (4). A similar relationship between
myocardial PKG activity and cardiomyocyte hypertrophy
was also manifest in aortic stenosis patients who had less
myocardial PKG activity and more cardiomyocyte hyper-
trophy when DM was a comorbidity (4,45).
Deﬁcient NO-cGMP-PKG signaling from endothelium
to myocardium also affects myocardial relaxation. In isolated
cardiac muscle preparations, loss of endocardial endothelium
delays onset of relaxation (32). High levels of peroxynitrite
increase protein phosphatase 2a activity, which lowers
phospholambam phosphorylation, reduces sarcoplasmic re-
ticular Ca2þ uptake, and increases diastolic cytosolic Ca2þ
(46). Both effects could explain the development of a high
resting tension at high pacing frequencies in cardiac muscle
strips isolated from HFPEF patients (8).
Apart from effects on myocardial relaxation, NO-cGMP-
PKG signaling from endothelium to myocardium also mod-
ulates myocardial stiffness. Coronary infusions of NO donors
acutely lowered diastolic LV stiffness in human controls, in
aortic stenosis, and in dilated cardiomyopathy (47). Chronic
inhibition of NO synthase in rats induced leftward dis-
placement of the diastolic LV pressure-volume relationship
with shrinkage of the LV unstressed volume (48) in contrast
to treatment with an endothelial NO synthase enhancer,
which attenuated diastolic LV dysfunction in a rat HFPEF
model (49). Oxidative stress blunting NO-mediated effects
on diastolic LV stiffness was evident in a hypertensive mouse
model (50). Sildenaﬁl reduced diastolic LV stiffness in an old
hypertensive dog model (51), in HFREF patients (52) and in
HFPEF patients with pulmonary hypertension (53). Ad-
ministration of sildenaﬁl to old hypertensive dogs lowered
diastolic LV stiffness through restored phosphorylation of the
N2B segment of titin (51). The giant cytoskeletal protein
titin acts as a bidirectional spring and is responsible for early
diastolic recoil and late diastolic distensibility of cardio-
myocytes. Its spring characteristics are modulated not only
through isoform shifts but also through phosphorylation
by protein kinases (54), such as protein kinase A (55), PKG
(56), or protein kinase C (57). Protein kinase A or PKG
makes titin more compliant in contrast to protein kinase C,
which makes it less compliant. Single cardiomyocytes isolated
from LV myocardium of HFPEF patients characteristically
have a high resting tension (2–4,27). This high resting
tension was attributed to hypophosphorylation of the N2B
segment of titin (58) because of low PKG activity (4) and was
corrected by in vitro administration of PKG (4).
Both stiff cardiomyocytes and ﬁbrosis contribute to dia-
stolic myocardial dysfunction. A recent histological study
of HFPEF myocardium revealed an increased collagen
volume fraction, higher expression of collagen type I, and
more collagen cross-linking, which all contributed to dia-
stolic LV dysfunction (6). The same investigators proposed
myocardial collagen deposition in HFPEF to result from
differentiation of ﬁbroblasts into myoﬁbroblasts because of
TGFb released by monocytes, which had migrated through
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vascular inﬂammation also directly favors proliferation of
ﬁbroblasts and myoﬁbroblasts because of reduced NO
bioavailability (42), which leaves proﬁbrotic action of
growth-promoting hormones such as endothelin-1, angio-
tensin II, and aldosterone unopposed (61).
Myocardial Afterload Excess
Arterial hypertension is the most prevalent comorbidity in
HFPEF (62). Although arterial hypertension has been
associated with oxidative stress and vascular inﬂammation
(63), arterial hypertension is usually perceived to induce
HFPEF through myocardial afterload excess (64). The new
HFPEF paradigm proposed in this review shifts emphasis to
microvascular inﬂammation, which lowers myocardial NO
bioavailability and removes the brake on prohypertrophic
stimuli triggered by myocardial afterload excess. This shift of
emphasis is further supported by the following arguments.
1. In all HFPEF registries and large outcome trials
(62,65,66), arterial hypertension in HFPEF consists
of increased systolic pressure (148 mm Hg) but
normal diastolic pressure (83 mm Hg). In HFPEF,
LV cavity dimensions are small, and, especially in the
presence of LV hypertrophy, the left ventricle operates
at a favorable Laplace relationship. LV systolic wall
stress therefore remains low despite increased LV
systolic pressure (67).Figure 2 Myocardial Dysfunction and Remodeling in HFPEF and HFREF
In HFPEF, myocardial dysfunction and remodeling are driven by endothelial inﬂammation and
because of ischemia, infection, or toxic agents. ROS trigger cardiomyocyte autophagy, apoptos
by ﬁbrous tissue. cGMP ¼ cyclic guanosine monophosphate; HFREF ¼ heart failure with redu2. Some population studies and outcome trials observed
a larger contribution to HFPEF development of
metabolic comorbidities than of arterial hypertension.
In the MONICA registry, left atrial enlargement was
strongly related to obesity, mildly related to age, and
unrelated to arterial hypertension (68). In ALL-HAT
(Antihypertensive and Lipid-Lowering treatment to
prevent Heart Attack Trial), which recruited 40,000
patients with arterial hypertension and 1 additional
risk factor, signiﬁcant baseline characteristics
discriminating between in-trial HFREF or HFPEF
development were, respectively, a history of coronary
heart disease favoring HFREF and a high body mass
index favoring HFPEF (69). In contrast, systolic or
diastolic blood pressure did not discriminate between
in-trial HFREF or HFPEF development.
3. Involvement in HFPEF of cardiac chambers other than
the left ventricle also provides a strong argument for
a microvascular inﬂammatory state driving myocardial
remodeling. When pulmonary hypertension secondary
to HFPEF (PH-HFPEF) is compared with primary
pulmonary hypertension, PH-HFPEF patients had
higher right atrial pressures with less right atrial dilation
(70), consistent with reduced right atrial compliance in
PH-HFPEF. This ﬁnding could not be attributed to
pulmonary arterial load, as mean pulmonary arterial
pressure was similar in both conditions but probably
related to the high prevalence of obesity in PH-HFPEFoxidative stress. In HFREF, oxidative stress originates in the cardiomyocytes
is, or necrosis. The latter attracts leukocytes. Dead cardiomyocytes are replaced
ced ejection fraction; other abbreviations as in Figure 1.
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267(46% vs. 15%). Similarly, in a study that compared
HFREF with HFPEF, pulmonary capillary wedge
pressure was equally increased, but left atrial volumewas
signiﬁcantly lower in HFPEF than in HFREF (71).
Finally, the same study assessed right ventricular systolic
performance and found an analogy to LV systolic per-
formance, higher right ventricular end-systolic elastance
in HFPEF than in HFREF.
HFPEF Versus HFREF
The new HFPEF paradigm substantially differs from the
paradigm proposed for HFREF, in which LV remodeling is
driven by progressive loss of cardiomyocytes (60) (Fig. 2).
This loss of cardiomyocytes results from various modalities
of cell death such as exaggerated autophagy, apoptosis, or
necrosis, all of which are triggered by oxidative stress present
within the cardiomyocyte (72–74). The latter usually results
from ischemia, infection, or toxicity. Excessive wall stress
because of cardiomyocyte loss shifts the balance in the
extracellular matrix between collagen deposition and degra-
dation (75). These alterations within the extracellular matrix
importantly contribute to LV dilation and eccentric LV
remodeling (75). In HFREF, replacement of dead car-
diomyocytes by collagen creates patchy areas of ﬁbrosis. A
comparative analysis of endomyocardial biopsy samples from
HFPEF and HFREF (3,27) indeed showed the presence
of replacement ﬁbrosis in HFREF but not in HFPEF.Figure 3 Myocardial Dysfunction and Remodeling in HFPEF, HFREF,
In HFPEF, myocardial dysfunction and remodeling are driven by endothelial oxidative stre
both mechanisms get superimposed. Abbreviations as in Figures 1 and 2.Furthermore, electron microscopic images of LV myocar-
dium revealed lower myoﬁlamentary density in HFREF than
in HFPEF, with some HFREF cardiomyocytes showing
areas of complete myoﬁbrillar loss (3). These biopsy ﬁndings
are consistent with cell death occurring in HFREF but not in
HFPEF. Potential bias of these results by the low frequency
of biopsy procurement in HFPEF patients cannot, however,
be excluded.
Apoptotic cardiomyocyte death also appears in late ec-
centric LV remodeling of transverse aortic constriction
mouse models (76). Oxidative stress because of upregulated
cardiac nicotinamide adenine dinucleotide phosphate oxidase
activity appears to be involved. These studies support a
sequence of events whereby myocardial pressure overload
initially triggers concentric hypertrophy followed later by
eccentric remodeling because of high oxidative stress and cell
death. This evolution has also been postulated in human
hypertension (77) but seriously questioned by longitudinal
cohort studies with sequential cardiac imaging (78). In these
studies, the evolution from concentric to eccentric remodel-
ing appeared to be rare in the absence of interval myocardial
infarction.
In advanced HFREF, systemic and coronary endothelial
dysfunction is also present and attributed to increased
plasma levels of TNF-a and IL-6 (79,80) (Fig. 3). However,
in contrast to HFPEF, the increased plasma levels of TNF-
a and IL-6 do not result from pre-existing comorbidities but
are reactive to the severity of HFREF as they relate to bothand Advanced HFREF
ss. In HFREF, oxidative stress originates in the cardiomyocytes. In advanced HFREF,
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depression of LV ejection fraction (80). Similar to HFPEF,
endothelial dysfunction affects diastolic LV function in
advanced HFREF, as evident from the relationship between
diastolic LV dysfunction and plasma levels of methylated
L-arginine metabolites, which impair NO production by
endothelial NO synthase (81).
Finally, although viral myocarditis usually evolves to
HFREF, a recent study found parvoviral myocarditis pre-
senting as HFPEF (31). In this study, however, the virus did
not affect the cardiomyocytes but the coronary endothelium.
This observation therefore ﬁts into the proposed paradigm
as HFPEF development was driven by coronary microvas-
cular endothelial inﬂammation.
Diagnostic and Therapeutic Implications
The new HFPEF paradigm suggests anthropometric
measures, comorbidities, vascular hyperemic responses, and
plasma markers of oxidative stress or of inﬂammation to be
useful for the diagnosis of HFPEF. No single HFPEF
registry has so far reported on waist circumference, which
provides an easy assessment of central obesity. The absence of
HFPEF development despite the presence of central obesity
probably relates to variable inﬁltration of visceral fat by
inﬂammatory cells (13,82). The importance of comorbidities
was recently reappraised (11,83–85), and forearm hyperemicFigure 4 Effects of Statin Treatment on HFPEF Myocardium
Statin-treated HFPEF patients (HFPEF statþ) have higher myocardial PKG activity assesse
serine239 (pVASP) to total VASP (pVASP/VASP ratio) (A), lower myocardial nitrotyrosine con
tension (Fpassive) (D). Abbreviations as in Figure 1.responses were shown to be impaired in HFPEF and to
provide diagnostic information (36). Finally, proinﬂammatory
cytokines are increased in HFPEF (24) and predict future
HFPEF development (23).
The newHFPEF paradigm also has important therapeutic
implications as it identiﬁes lowmyocardial NO bioavailability
as a deﬁcient brake on prohypertrophic stimuli in HFPEF-
related LV remodeling. Future HFPEF treatment strategies
should therefore aim at curing both arterial hypertension
(86) and endothelial dysfunction. The latter can be achieved
through correction of comorbidities and through use of
NO donors, PDE-5 inhibitors, and substances with anti-
oxidative properties such as statins and resveratrol. Long-term
use of isosorbide dinitrate combined with the antioxidant
hydralazine improved the outcome of HFREF patients in
V-HEFT I (Vasodilator-Heart Failure Trials) and A-HEFT
(African-American Heart Failure Trial) (87,88). Many A-
HEFT patients were obese or had DM, and their clinical
proﬁle therefore overlaps with HFPEF. Long-term use of the
PDE5 inhibitor sildenaﬁl improved diastolic LV dysfunction
in both HFREF and HFPEF, improved clinical status in
HFREF, and reduced pulmonary hypertension in HFPEF
(52,53). No effect of sildenaﬁl on exercise tolerance was
however observed in a large HFPEF outcome trial (RELAX
study [Evaluating the Effectiveness of Sildenaﬁl at Improv-
ing Health Outcomes and Exercise Ability in People With
Diastolic Heart Failure; NCT00763867]).d by the ratio of vasodilatory-stimulated phosphoprotein (VASP) phosphorylated at
tent (B), smaller cardiomyocyte diameter (MyD) (C), and lower cardiomyocyte resting
JACC Vol. 62, No. 4, 2013 Paulus and Tschöpe
July 23, 2013:263–71 Myocardial Remodeling in HFPEF
269The new HFPEF paradigm also supports the use of
statins. Statins exert rapid and direct effects on endothelial
redox balance, which are independent of low-density lipo-
protein lowering and consist of reduced superoxide anion
production and restored NO bioavailability (89). These
effects reach adjacent cardiomyocytes and ﬁbroblasts, as
evident in experimental hypertension or hypercholesterol-
emia from regression of LV hypertrophy, prevention of
myocardial ﬁbrosis, and amelioration of diastolic LV
dysfunction (90). A retrospective analysis of a recent clinical
study looking at myocardial nitrotyrosine content, PKG ac-
tivity, hypertrophy, and cardiomyocyte stiffness in HFPEF
patients (4) revealed statin-treated patients to have less
nitrotyrosine, more PKG activity, less cardiomyocyte hy-
pertrophy, and lower cardiomyocyte resting tension (Fig. 4).
These ﬁndings are in line with the positive outcome of
a small study that showed statin use to lower the mortality of
HFPEF patients (91). A neutral outcome of statin use was,
however, also reported in a large randomized HF trial in
a subgroup of patients with relatively preserved LV ejection
fraction (>40%) (92).
In HFPEF, use of angiotensin-converting enzyme inhib-
itors (ACEIs) and angiotensin II receptor blockers (ARBs)
has so far been disappointing, with all large trials showing
a neutral outcome (93). This neutral outcome seems to be at
odds with the proposed HFPEF paradigm because ACEIs
and ARBs are known to exert a vasculoprotective effect,
which was evident in several large outcome trials from
a reduced incidence of new atherosclerotic events (94,95). A
protective effect on the macrovasculature does not, however,
necessarily imply restored endothelial function. This was
illustrated by PERFECT (PERindopril-Function of the
Endothelium in Coronary artery disease Trial), a substudy of
EUROPA (EURopean trial On reduction of cardiac events
with Perindopril in stable coronary Artery disease) (96). At
36 months follow-up, PERFECT reported no signiﬁcant
improvement (p ¼ 0.23) in ﬂow-mediated brachial artery
dilation when taking perindopril 8 mg once daily in contrast
to the signiﬁcant reduction (p ¼ 0.001) in myocardial
infarctions observed with the same perindopril regimen in
the EUROPA trial (95). A recent meta-analysis looking at
the effects of ACEIs and ARBs on endothelial dysfunction
emphasizes the variability of the response with the absence of
a signiﬁcant effect, especially in the presence of comorbidities
featuring inﬂammation and systemic oxidative stress such as
obesity, DM, and rheumatoid arthritis (97).
Conclusions
In HFPEF, comorbidities contribute to a systemic inﬂam-
matory state, which induces oxidative stress in the coronary
microvascular endothelium. This reduces myocardial NO
bioavailability and leads to reduced PKG activity in car-
diomyocytes, which therefore become stiff and hypertro-
phied. Myocardial remodeling in HFPEF differs from
myocardial remodeling in HFREF, which is driven bycardiomyocyte death because of oxidative stress originating
in the cardiomyocytes as a result of ischemia, infection, or
toxicity. The new HFPEF paradigm has important diag-
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